

# Argyro Syngelaki

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/409962/argyro-syngelaki-publications-by-citations.pdf>  
**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

181 papers	9,849 citations	57 h-index	95 g-index
207 ext. papers	12,158 ext. citations	5 avg, IF	6.43 L-index

#	Paper	IF	Citations
181	Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 613-622	59.2	926
180	Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. <i>Fetal Diagnosis and Therapy</i> , <b>2013</b> , 33, 8-15	2.4	359
179	Challenges in the diagnosis of fetal non-chromosomal abnormalities at 11-13 weeks. <i>Prenatal Diagnosis</i> , <b>2011</b> , 31, 90-102	3.2	312
178	Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. <i>Prenatal Diagnosis</i> , <b>2011</b> , 31, 66-74	3.2	291
177	Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population. <i>American Journal of Obstetrics and Gynecology</i> , <b>2012</b> , 207, 374.e1-6	6.4	265
176	Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation. <i>American Journal of Obstetrics and Gynecology</i> , <b>2016</b> , 214, 103.e1-103.e12	6.4	251
175	Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 434-43	59.2	244
174	Fetal fraction in maternal plasma cell-free DNA at 11-13 weeksTgestation: relation to maternal and fetal characteristics. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2013</b> , 41, 26-32	5.8	244
173	Maternal age and adverse pregnancy outcome: a cohort study. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2013</b> , 42, 634-43	5.8	204
172	Chromosome-selective sequencing of maternal plasma cell-free DNA for first-trimester detection of trisomy 21 and trisomy 18. <i>American Journal of Obstetrics and Gynecology</i> , <b>2012</b> , 206, 322.e1-5	6.4	200
171	Competing risks model in screening for preeclampsia by maternal characteristics and medical history. <i>American Journal of Obstetrics and Gynecology</i> , <b>2015</b> , 213, 62.e1-62.e10	6.4	198
170	Validation of targeted sequencing of single-nucleotide polymorphisms for non-invasive prenatal detection of aneuploidy of chromosomes 13, 18, 21, X, and Y. <i>Prenatal Diagnosis</i> , <b>2013</b> , 33, 575-9	3.2	174
169	ASPRE trial: performance of screening for preterm pre-eclampsia. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2017</b> , 50, 492-495	5.8	161
168	Combined screening for preeclampsia and small for gestational age at 11-13 weeks. <i>Fetal Diagnosis and Therapy</i> , <b>2013</b> , 33, 16-27	2.4	159
167	Multicenter screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeksT gestation: comparison with NICE guidelines and ACOG recommendations. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2017</b> , 49, 756-760	5.8	150
166	Prediction of gestational diabetes mellitus by maternal factors and biomarkers at 11 to 13 weeks. <i>Prenatal Diagnosis</i> , <b>2011</b> , 31, 135-41	3.2	147
165	Protocol for measurement of mean arterial pressure at 11-13 weeksTgestation. <i>Fetal Diagnosis and Therapy</i> , <b>2012</b> , 31, 42-8	2.4	144

164	A competing risks model in early screening for preeclampsia. <i>Fetal Diagnosis and Therapy</i> , <b>2012</b> , 32, 171-8.4	8.4	144
163	Accuracy of competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeksTgestation. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2017</b> , 49, 751-755	5.8	138
162	Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2018</b> , 51, 743-750	5.8	131
161	Screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeksTgestation. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2018</b> , 52, 186-195	5.8	118
160	A Randomized Trial of a Cervical Pessary to Prevent Preterm Singleton Birth. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 1044-52	59.2	111
159	Fetal fraction in maternal plasma cell-free DNA at 11-13 weeksTgestation: effect of maternal and fetal factors. <i>Fetal Diagnosis and Therapy</i> , <b>2012</b> , 31, 237-43	2.4	111
158	Fetal Medicine Foundation fetal and neonatal population weight charts. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2018</b> , 52, 44-51	5.8	105
157	Birthweight with gestation and maternal characteristics in live births and stillbirths. <i>Fetal Diagnosis and Therapy</i> , <b>2012</b> , 32, 156-65	2.4	96
156	Maternal serum placental protein 13 at 11-13 weeks of gestation in preeclampsia. <i>Prenatal Diagnosis</i> , <b>2009</b> , 29, 1103-8	3.2	92
155	Diagnosis of fetal non-chromosomal abnormalities on routine ultrasound examination at 11-13 weeksTgestation. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2019</b> , 54, 468-476	5.8	91
154	Cervical pessary placement for prevention of preterm birth in unselected twin pregnancies: a randomized controlled trial. <i>American Journal of Obstetrics and Gynecology</i> , <b>2016</b> , 214, 3.e1-9	6.4	90
153	Trisomy 13 detection in the first trimester of pregnancy using a chromosome-selective cell-free DNA analysis method. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2013</b> , 41, 21-5	5.8	88
152	First-trimester screening for trisomies 21, 18 and 13 by ultrasound and biochemical testing. <i>Fetal Diagnosis and Therapy</i> , <b>2014</b> , 35, 118-26	2.4	87
151	The role and interaction of imprinted genes in human fetal growth. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , <b>2015</b> , 370, 20140074	5.8	85
150	Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history. <i>American Journal of Obstetrics and Gynecology</i> , <b>2017</b> , 217, 585.e1-585.e5	6.4	85
149	A comprehensive analysis of common genetic variation around six candidate loci for intrahepatic cholestasis of pregnancy. <i>American Journal of Gastroenterology</i> , <b>2014</b> , 109, 76-84	0.7	84
148	Predictive performance of the competing risk model in screening for preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , <b>2019</b> , 220, 199.e1-199.e13	6.4	83
147	First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2013</b> , 42, 41-50	5.8	83

146	Prenatal detection of fetal triploidy from cell-free DNA testing in maternal blood. <i>Fetal Diagnosis and Therapy</i> , <b>2014</b> , 35, 212-7	2.4	80
145	Maternal plasma cell-free fetal and maternal DNA at 11-13 weeksTgestation: relation to fetal and maternal characteristics and pregnancy outcomes. <i>Fetal Diagnosis and Therapy</i> , <b>2013</b> , 33, 215-23	2.4	80
144	The 11-13-week scan: diagnosis and outcome of holoprosencephaly, exomphalos and megacystis. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2010</b> , 36, 10-4	5.8	80
143	Cell-free DNA analysis for trisomy risk assessment in first-trimester twin pregnancies. <i>Fetal Diagnosis and Therapy</i> , <b>2014</b> , 35, 204-11	2.4	78
142	First-trimester screening for spontaneous preterm delivery with maternal characteristics and cervical length. <i>Fetal Diagnosis and Therapy</i> , <b>2012</b> , 31, 154-61	2.4	77
141	Birth weight in live births and stillbirths. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2016</b> , 48, 602-606	5.8	74
140	Contribution of fetal tricuspid regurgitation in first-trimester screening for major cardiac defects. <i>Obstetrics and Gynecology</i> , <b>2011</b> , 117, 1384-1391	4.9	72
139	Umbilical and fetal middle cerebral artery Doppler at 35-37 weeksTgestation in the prediction of adverse perinatal outcome. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2015</b> , 46, 82-92	5.8	70
138	Prediction of spontaneous preterm delivery from maternal factors, obstetric history and placental perfusion and function at 11-13 weeks. <i>Prenatal Diagnosis</i> , <b>2011</b> , 31, 75-83	3.2	69
137	Chronic hypertension and adverse pregnancy outcome: a cohort study. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2017</b> , 50, 228-235	5.8	68
136	Ultrasonographic estimation of fetal weight: development of new model and assessment of performance of previous models. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2018</b> , 52, 35-43	5.8	66
135	Assessment of fetal sex chromosome aneuploidy using directed cell-free DNA analysis. <i>Fetal Diagnosis and Therapy</i> , <b>2014</b> , 35, 1-6	2.4	66
134	Maternal hemodynamics at 11-13 weeksTgestation and risk of pre-eclampsia. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2012</b> , 40, 28-34	5.8	66
133	Fetal Medicine Foundation reference ranges for umbilical artery and middle cerebral artery pulsatility index and cerebroplacental ratio. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2019</b> , 53, 465-472	5.8	64
132	An expanded role for heterozygous mutations of ABCB4, ABCB11, ATP8B1, ABCC2 and TJP2 in intrahepatic cholestasis of pregnancy. <i>Scientific Reports</i> , <b>2017</b> , 7, 11823	4.9	63
131	Normal ranges of embryonic length, embryonic heart rate, gestational sac diameter and yolk sac diameter at 6-10 weeks. <i>Fetal Diagnosis and Therapy</i> , <b>2010</b> , 28, 207-19	2.4	63
130	Prediction and prevention of small-for-gestational-age neonates: evidence from SPREE and ASPRE. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2018</b> , 52, 52-59	5.8	62
129	Maternal racial origin and adverse pregnancy outcome: a cohort study. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2013</b> , 41, 278-85	5.8	62

128	Accuracy of first-trimester combined test in screening for trisomies 21, 18 and 13. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2017</b> , 49, 714-720	5.8	61
127	Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , <b>2017</b> , 217, 685.e1-685.e5	6.4	59
126	Hidden high rate of pre-eclampsia in twin compared with singleton pregnancy. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2017</b> , 50, 88-92	5.8	58
125	Contribution of ductus venosus Doppler in first-trimester screening for major cardiac defects. <i>Fetal Diagnosis and Therapy</i> , <b>2011</b> , 29, 127-34	2.4	57
124	Prognostic and mechanistic potential of progesterone sulfates in intrahepatic cholestasis of pregnancy and pruritus gravidarum. <i>Hepatology</i> , <b>2016</b> , 63, 1287-98	11.2	56
123	Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin on length of stay in the neonatal intensive care unit. <i>American Journal of Obstetrics and Gynecology</i> , <b>2018</b> , 218, 612.e1-612.e6	6.4	54
122	Sonographic markers of aneuploidies at 6-10 weeks of gestation. <i>Early Human Development</i> , <b>2011</b> , 87, 453-6	2.2	51
121	Body mass index at 11-13 weeksTgestation and pregnancy complications. <i>Fetal Diagnosis and Therapy</i> , <b>2011</b> , 30, 250-65	2.4	48
120	Ultrasonographic prediction of early miscarriage. <i>Human Reproduction</i> , <b>2011</b> , 26, 1685-92	5.7	47
119	Maternal serum placental growth factor in prospective screening for aneuploidies at 8-13 weeksT gestation. <i>Fetal Diagnosis and Therapy</i> , <b>2012</b> , 31, 87-93	2.4	46
118	Replacing the combined test by cell-free DNA testing in screening for trisomies 21, 18 and 13: impact on the diagnosis of other chromosomal abnormalities. <i>Fetal Diagnosis and Therapy</i> , <b>2014</b> , 35, 174-84	2.4	45
117	First-Trimester Screening for Gestational Diabetes Mellitus Based on Maternal Characteristics and History. <i>Fetal Diagnosis and Therapy</i> , <b>2015</b> , 38, 14-21	2.4	44
116	Validation of metabolomic models for prediction of early-onset preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , <b>2015</b> , 213, 530.e1-530.e10	6.4	43
115	Fetal fraction estimate in twin pregnancies using directed cell-free DNA analysis. <i>Fetal Diagnosis and Therapy</i> , <b>2014</b> , 35, 199-203	2.4	43
114	First-trimester prediction of macrosomia. <i>Fetal Diagnosis and Therapy</i> , <b>2011</b> , 29, 139-47	2.4	43
113	A robust second-generation genome-wide test for fetal aneuploidy based on shotgun sequencing cell-free DNA in maternal blood. <i>Prenatal Diagnosis</i> , <b>2013</b> , 33, 707-10	3.2	42
112	Prediction of small for gestational age neonates: screening by maternal factors, fetal biometry, and biomarkers at 35-37 weeksTgestation. <i>American Journal of Obstetrics and Gynecology</i> , <b>2019</b> , 220, 486.e1-486.e11	6.4	41
111	First-trimester contingent screening for trisomies 21, 18 and 13 by biomarkers and maternal blood cell-free DNA testing. <i>Fetal Diagnosis and Therapy</i> , <b>2014</b> , 35, 185-92	2.4	40

110	First trimester maternal serum free human chorionic gonadotropin and pregnancy-associated plasma protein A in pregnancies complicated by diabetes mellitus. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , <b>2012</b> , 119, 410-6	3.7	40
109	Routine assessment of cerebroplacental ratio at 35-37 weeks gestation in the prediction of adverse perinatal outcome. <i>American Journal of Obstetrics and Gynecology</i> , <b>2019</b> , 221, 65.e1-65.e18	6.4	39
108	Screening for pre-eclampsia at 35-37 weeks gestation. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2018</b> , 52, 501-506	5.8	39
107	Prevalence and outcome of absence of ductus venosus at 11(+0) to 13(+6) weeks. <i>Fetal Diagnosis and Therapy</i> , <b>2011</b> , 30, 35-40	2.4	37
106	Second-trimester uterine artery Doppler in the prediction of stillbirths. <i>Fetal Diagnosis and Therapy</i> , <b>2013</b> , 33, 28-35	2.4	36
105	Metabolomic prediction of fetal congenital heart defect in the first trimester. <i>American Journal of Obstetrics and Gynecology</i> , <b>2014</b> , 211, 240.e1-240.e14	6.4	34
104	Paternally expressed, imprinted insulin-like growth factor-2 in chorionic villi correlates significantly with birth weight. <i>PLoS ONE</i> , <b>2014</b> , 9, e85454	3.7	33
103	First trimester screening for gestational diabetes mellitus by maternal factors and markers of inflammation. <i>Metabolism: Clinical and Experimental</i> , <b>2016</b> , 65, 131-7	12.7	32
102	Prediction of large-for-gestational-age neonates: screening by maternal factors and biomarkers in the three trimesters of pregnancy. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2016</b> , 47, 332-9	5.8	31
101	Prediction of stillbirth from maternal demographic and pregnancy characteristics. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2016</b> , 48, 607-612	5.8	30
100	Maternal serum placental growth factor at 11-13 weeks gestation and fetal cardiac defects. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2013</b> , 42, 169-74	5.8	30
99	Value of routine ultrasound examination at 35-37 weeks gestation in diagnosis of fetal abnormalities. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2020</b> , 55, 75-80	5.8	30
98	Prediction of imminent preeclampsia at 35-37 weeks gestation. <i>American Journal of Obstetrics and Gynecology</i> , <b>2019</b> , 220, 584.e1-584.e11	6.4	29
97	First-trimester biochemical markers of placentation in screening for gestational diabetes mellitus. <i>Metabolism: Clinical and Experimental</i> , <b>2015</b> , 64, 1485-9	12.7	29
96	Impact of holoprosencephaly, exomphalos, megacystis and increased nuchal translucency on first-trimester screening for chromosomal abnormalities. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2017</b> , 50, 45-48	5.8	29
95	Contribution of method of conception on pregnancy outcome after the 11-13 weeks scan. <i>Fetal Diagnosis and Therapy</i> , <b>2011</b> , 30, 9-22	2.4	28
94	Early Detection of Preeclampsia Using Circulating Small non-coding RNA. <i>Scientific Reports</i> , <b>2018</b> , 8, 34014	4.9	27
93	Integrated Proteomic and Metabolomic prediction of Term Preeclampsia. <i>Scientific Reports</i> , <b>2017</b> , 7, 16189	4.9	27



92	A mixture model of ductus venosus pulsatility index in screening for aneuploidies at 11-13 weeksT gestation. <i>Fetal Diagnosis and Therapy</i> , <b>2012</b> , 31, 221-9	2.4	27
91	Management of pregnancies after combined screening for pre-eclampsia at 19-24 weeksT gestation. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2018</b> , 52, 365-372	5.8	27
90	Two-stage screening for preterm preeclampsia at 11-13 weeksTgestation. <i>American Journal of Obstetrics and Gynecology</i> , <b>2019</b> , 220, 197.e1-197.e11	6.4	24
89	Prediction of preeclampsia by uterine artery Doppler at 20-24 weeksTgestation. <i>Fetal Diagnosis and Therapy</i> , <b>2013</b> , 34, 241-7	2.4	24
88	Outcome of twin pregnancy with two live fetuses at 11-13 weeksTgestation. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2020</b> , 55, 32-38	5.8	23
87	Maternal hemodynamics at 11-13 weeks of gestation in pregnancies delivering small for gestational age neonates. <i>Fetal Diagnosis and Therapy</i> , <b>2012</b> , 32, 231-8	2.4	22
86	Competing-risks model in screening for pre-eclampsia in twin pregnancy according to maternal factors and biomarkers at 11-13 weeksTgestation. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2017</b> , 50, 589-595	5.8	21
85	Diagnosis of major heart defects by routine first-trimester ultrasound examination: association with increased nuchal translucency, tricuspid regurgitation and abnormal flow in ductus venosus. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2020</b> , 55, 637-644	5.8	21
84	Metabolomic determination of pathogenesis of late-onset preeclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2017</b> , 30, 658-664	2	20
83	Posterior brain in fetuses with trisomy 18, trisomy 13 and triploidy at 11 to 13 weeksTgestation. <i>Prenatal Diagnosis</i> , <b>2012</b> , 32, 854-8	3.2	20
82	Screening for trisomies in dichorionic twins by measurement of fetal nuchal translucency thickness according to the mixture model. <i>Prenatal Diagnosis</i> , <b>2011</b> , 31, 16-21	3.2	20
81	Early vaginal progesterone versus placebo in twin pregnancies for the prevention of spontaneous preterm birth: a randomized, double-blind trial. <i>American Journal of Obstetrics and Gynecology</i> , <b>2021</b> , 224, 86.e1-86.e19	6.4	20
80	Competing-risks model in screening for pre-eclampsia in twin pregnancy by maternal characteristics and medical history. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2017</b> , 50, 501-506	5.8	19
79	Association of chronic hypertension with birth of small-for-gestational-age neonate. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2017</b> , 50, 361-366	5.8	19
78	Prediction of small-for-gestational-age neonates at 35-37 weeksTgestation: contribution of maternal factors and growth velocity between 20 and 36 weeks. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2019</b> , 53, 488-495	5.8	19
77	Two-stage approach for prediction of small-for-gestational-age neonate and adverse perinatal outcome by routine ultrasound examination at 35-37 weeksTgestation. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2019</b> , 54, 484-491	5.8	18
76	First-trimester screening for trisomy 21 using alpha-fetoprotein. <i>Fetal Diagnosis and Therapy</i> , <b>2011</b> , 30, 215-8	2.4	18
75	Intertwin discordance in fetal size at 11-13 weeksTgestation and pregnancy outcome. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2020</b> , 55, 189-197	5.8	18

74	Diagnosis of fetal defects in twin pregnancies at routine 11-13-week ultrasound examination. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2020</b> , 55, 474-481	5.8	17
73	Screening for pre-eclampsia at 11-13 weeksTgestation: use of pregnancy-associated plasma protein-A, placental growth factor or both. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2020</b> , 56, 400-407	5.8	17
72	Impaired placentation in women with chronic hypertension who develop pre-eclampsia. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2017</b> , 50, 496-500	5.8	16
71	Fetal major cardiac defects and placental dysfunction at 11-13 weeksTgestation. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2018</b> , 51, 194-198	5.8	16
70	Diet and exercise for preeclampsia prevention in overweight and obese pregnant women: systematic review and meta-analysis. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2019</b> , 32, 3495-3501	5.8	16
69	Proposed clinical management of pregnancies after combined screening for pre-eclampsia at 30-34 weeksTgestation. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2017</b> , 49, 194-200	5.8	16
68	Quantitative ELISAs for serum soluble LHCGR and hCG-LHCGR complex: potential diagnostics in first trimester pregnancy screening for stillbirth, Down's syndrome, preterm delivery and preeclampsia. <i>Reproductive Biology and Endocrinology</i> , <b>2012</b> , 10, 113	5	15
67	Performance of the neoBona test: a new paired-end massively parallel shotgun sequencing approach for cell-free DNA-based aneuploidy screening. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2017</b> , 49, 460-464	5.8	14
66	A case-control study of maternal periconceptual and pregnancy recreational drug use and fetal malformation using hair analysis. <i>PLoS ONE</i> , <b>2014</b> , 9, e111038	3.7	14
65	Increased nuchal translucency at 11-13 weeksTgestation and outcome in twin pregnancy. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2020</b> , 55, 318-325	5.8	14
64	Pravastatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsia. <i>Circulation</i> , <b>2021</b> , 144, 670-679	16.7	14
63	Routine ultrasound at 32 vs 36 weeksTgestation: prediction of small-for-gestational-age neonates. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2019</b> , 53, 761-768	5.8	13
62	A retrospective multicenter study of the natural history of fetal ovarian cysts. <i>Journal of Pediatric Surgery</i> , <b>2018</b> , 53, 2019-2022	2.6	13
61	Maternal hemodynamics in normal pregnancies at 11-13 weeksTgestation. <i>Fetal Diagnosis and Therapy</i> , <b>2012</b> , 32, 179-85	2.4	13
60	Prediction of stillbirth from maternal factors, fetal biometry and uterine artery Doppler at 19-24 weeks. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2016</b> , 48, 624-630	5.8	13
59	Prediction of small-for-gestational-age neonates at 35-37 weeksTgestation: contribution of maternal factors and growth velocity between 32 and 36 weeks. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2019</b> , 53, 630-637	5.8	12
58	Maternal serum soluble endoglin at 30-33 weeks in the prediction of preeclampsia. <i>Fetal Diagnosis and Therapy</i> , <b>2013</b> , 33, 149-55	2.4	12
57	Prediction of outcome in dichorionic twin pregnancies at 6-10 weeksTgestation. <i>American Journal of Obstetrics and Gynecology</i> , <b>2011</b> , 205, 348.e1-5	6.4	12



56	Impact of new definitions of preeclampsia at term on identification of adverse maternal and perinatal outcomes. <i>American Journal of Obstetrics and Gynecology</i> , <b>2021</b> , 224, 518.e1-518.e11	6.4	12
55	Can Staining of Damaged Proteins in Urine Effectively Predict Preeclampsia?. <i>Fetal Diagnosis and Therapy</i> , <b>2017</b> , 41, 23-31	2.4	11
54	Two-stage approach for risk estimation of fetal trisomy 21 and other aneuploidies using computational intelligence systems. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2018</b> , 51, 503-508	5.8	11
53	Chorionic villus sampling at 11 to 13 weeks of gestation and hypertensive disorders in pregnancy. <i>Obstetrics and Gynecology</i> , <b>2010</b> , 116, 374-380	4.9	11
52	Reference Ranges for the Size of the Fetal Cardiac Outflow Tracts From 13 to 36 Weeks Gestation: A Single-Center Study of Over 7000 Cases. <i>Circulation: Cardiovascular Imaging</i> , <b>2018</b> , 11, e007575	3.9	9
51	Screening for trisomy at 11-13 weeksTgestation: use of pregnancy-associated plasma protein-A, placental growth factor or both. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2020</b> , 56, 408-415	5.8	8
50	First-trimester uterine artery Doppler examination in pregnancies complicated by gestational diabetes mellitus with or without pre-eclampsia. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2013</b> , 42, 525-529	5.8	8
49	First-trimester markers of aneuploidy in women positive for HIV. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , <b>2011</b> , 118, 844-8	3.7	8
48	First-trimester screening for trisomy 21 with adjustment for biochemical results of previous pregnancies. <i>Fetal Diagnosis and Therapy</i> , <b>2011</b> , 30, 194-202	2.4	8
47	First-trimester screening for trisomies in pregnancies with vanishing twin. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2020</b> , 55, 326-331	5.8	8
46	Prenatal incidence of isolated right aortic arch and double aortic arch. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2021</b> , 34, 2985-2990	2	7
45	Association between maternal haemoglobin at 27-29weeks gestation and intrauterine growth restriction. <i>Pregnancy Hypertension</i> , <b>2015</b> , 5, 339-45	2.6	7
44	Maternal serum activin-A at 30-33 weeks in the prediction of preeclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2013</b> , 26, 733-7	2	7
43	Competing-risks model for prediction of small-for-gestational-age neonate from maternal characteristics and serum pregnancy-associated plasma protein-A at 11-13 weeksTgestation. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2020</b> , 56, 541-548	5.8	7
42	Cell-free DNA testing of maternal blood in screening for trisomies in twin pregnancy: updated cohort study at 10-14 weeks and meta-analysis. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2021</b> , 58, 178-189	5.8	7
41	Competing-risks model for prediction of small-for-gestational-age neonate from biophysical and biochemical markers at 11-13 weeksTgestation. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2021</b> , 57, 52-61	5.8	7
40	Association between insulin resistance and preeclampsia in obese non-diabetic women receiving metformin. <i>Obstetric Medicine</i> , <b>2017</b> , 10, 170-173	1.5	6
39	Metformin use in obese mothers is associated with improved cardiovascular profile in the offspring. <i>American Journal of Obstetrics and Gynecology</i> , <b>2020</b> , 223, 246.e1-246.e10	6.4	6

38	Galectin-7 Impairs Placentation and Causes Preeclampsia Features in Mice. <i>Hypertension</i> , <b>2020</b> , 76, 1185-1194	8.5	6
37	Impaired placental perfusion and major fetal cardiac defects. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2019</b> , 53, 68-72	5.8	6
36	Prediction of pre-eclampsia in twin pregnancy by maternal factors and biomarkers at 11-13 weeksT gestation: data from EVENTS trial. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2021</b> , 57, 257-265	5.8	6
35	Metformin in Pregnancy Study (MiPS): protocol for a systematic review with individual patient data meta-analysis. <i>BMJ Open</i> , <b>2020</b> , 10, e036981	3	5
34	Fetal intra-abdominal bowel dilation in prediction of complex gastroschisis. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2019</b> , 54, 376-380	5.8	4
33	Effect of chorionic villus sampling on uterine artery Doppler. <i>Fetal Diagnosis and Therapy</i> , <b>2010</b> , 28, 9-13	2.4	4
32	Twin pregnancy with two live fetuses at 11-13 weeks: effect of one fetal death on pregnancy outcome. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2020</b> , 55, 482-488	5.8	4
31	Re-evaluating diagnostic thresholds for intrahepatic cholestasis of pregnancy: case-control and cohort study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , <b>2021</b> , 128, 1635-1644	3.7	4
30	Stratification of pregnancy care based on risk of pre-eclampsia derived from uterine artery Doppler at 19-24 weeksTgestation. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2021</b> , 58, 67-76	5.8	4
29	First-trimester metabolomic prediction of stillbirth. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2019</b> , 32, 3435-3441	2	4
28	Maternal hemoglobin at 27-29 weeksTgestation and severity of pre-eclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2015</b> , 28, 1575-80	2	3
27	Second- and third-trimester serum levels of growth-differentiation factor-15 in prediction of pre-eclampsia. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2020</b> , 56, 879-884	5.8	3
26	Maternal serum human placental growth hormone at 11 to 13 weeks in trisomy 21 and trisomy 18 pregnancies. <i>Prenatal Diagnosis</i> , <b>2010</b> , 30, 212-5	3.2	3
25	Competing-risks model for prediction of small-for-gestational-age neonate from estimated fetal weight at 19-24 weeksTgestation. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2021</b> , 57, 917-924	5.8	3
24	Effective Aspirin Treatment of Women at Risk for Preeclampsia Delays the Metabolic Clock of Gestation. <i>Hypertension</i> , <b>2021</b> , 78, 1398-1410	8.5	3
23	Fetal loss after chorionic villus sampling in twin pregnancy. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2021</b> , 58, 48-55	5.8	3
22	8.4 Serum beta defensin concentration in the first trimester is related to genotype, and is higher in women who develop PPROM and deliver before 34 weeks. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , <b>2014</b> , 99, A12.1-A12	4.7	2
21	Yolk sac diameter in early pregnancy in maternal diabetes mellitus. <i>Gynecologic and Obstetric Investigation</i> , <b>2012</b> , 73, 16-20	2.5	2

20	Noninvasive Prenatal Testing for Fetal Trisomies in a Routinely Screened First-Trimester Population. <i>Obstetrical and Gynecological Survey</i> , <b>2013</b> , 68, 173-175	2.4	2
19	Vaginal progesterone for prevention of preterm birth and adverse perinatal outcomes in twin gestation with a short cervix: updated individual patient data meta-analysis.. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2021</b> ,	5.8	2
18	Risk of fetal loss after chorionic villus sampling in twin pregnancies derived from propensity score matching analysis. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2021</b> ,	5.8	2
17	Stratification of pregnancy care based on risk of pre-eclampsia derived from biophysical and biochemical markers at 19-24 weeksTgestation. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2021</b> , 58, 360-368	5.8	2
16	First trimester combined screening in patients with systemic lupus erythematosus: impact of pre-analytical variables on risk assessment. <i>Clinical Rheumatology</i> , <b>2019</b> , 38, 1251-1255	3.9	1
15	A Randomized Trial of a Cervical Pessary to Prevent Preterm Singleton Birth. <i>Obstetrical and Gynecological Survey</i> , <b>2016</b> , 71, 392-393	2.4	1
14	OS084. Maternal haemodynamics at 11-13 weeks of gestation and adverse pregnancy outcomes. <i>Pregnancy Hypertension</i> , <b>2012</b> , 2, 223-4	2.6	1
13	Serum leukotriene B4 and hydroxyeicosatetraenoic acid in the prediction of pre-eclampsia. <i>Placenta</i> , <b>2021</b> , 103, 76-81	3.4	1
12	Contingent screening in stratification of pregnancy care based on risk of pre-eclampsia at 19-24 weeksTgestation. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2021</b> , 58, 553-560	5.8	1
11	STATIN trial: predictive performance of competing-risk model in screening for pre-eclampsia at 35-37 weeksTgestation. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2021</b> ,	5.8	1
10	Reference Ranges for Pulsed-Wave Doppler of the Fetal Cardiac Inflow and Outflow Tracts from 13 to 36WeeksTgestation. <i>Journal of the American Society of Echocardiography</i> , <b>2021</b> , 34, 1007-1016.e10	5.8	1
9	Second and third trimester serum levels of HtrA1 in pregnancies affected by pre-eclampsia. <i>Placenta</i> , <b>2021</b> , 106, 1-6	3.4	0
8	Competing risks model for prediction of small-for-gestational-age neonates from biophysical markers at 19 to 24 weeksTgestation. <i>American Journal of Obstetrics and Gynecology</i> , <b>2021</b> , 225, 530.e1-530.e19	6.4	0
7	Screening for late preeclampsia at 35-37 weeks by the urinary Congo-red dot paper test. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2021</b> , 1-5	2	0
6	Fetal fraction of cell free DNA in screening for hypertensive disorders at 11-13 weeks. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2021</b> , 1-6	2	0
5	Is variation in copy number of the human beta defensin gene cluster associated with preterm birth?. <i>Lancet, The</i> , <b>2015</b> , 385 Suppl 1, S47	4.0	0
4	OS027. Ethnicity and adverse pregnancy outcomes: A cohort study. <i>Pregnancy Hypertension</i> , <b>2012</b> , 2, 190-1	2.6	0
3	4.2 Variation in Beta Defensin 1 Genotype is Associated with Preterm Birth. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , <b>2013</b> , 98, A4.1-A4	4.7	0

- 2 Recreational drug use is associated with a variety of fetal malformations. *Archives of Disease in Childhood: Fetal and Neonatal Edition*, **2010**, 95, Fa21-Fa21 4·7
- 1 Artificial Neural Networks to Investigate the Importance and the Sensitivity to Various Parameters Used for the Prediction of Chromosomal Abnormalities. *International Federation for Information Processing*, **2012**, 46-55